

Supplemental Material

Table S1. Estimated outcomes with blood-based and stool-based test under various adherence and blood-based test adenoma sensitivity scenarios.

Screening Test	Adherence	Total COLs	CRC cases	CRC deaths	LY with CRC	LYG	CRC incidence reduction	CRC mortality reduction
No screening	--	80.1	80.1	36.8	643.1	0.000	0.0%	0.0%
mt-sDNA	30%	1084.2	40.1	15.5	402.8	248.1	50.0%	57.8%
	40%	1208.4	36.6	13.9	375.1	269.1	54.3%	62.2%
	50%	1299.0	34.3	12.8	356.2	284.1	57.2%	65.3%
	60%	1371.7	32.6	12.0	343.1	292.6	59.3%	67.4%
	70%	1428.2	31.4	11.4	332.4	299.6	60.8%	68.9%
	100%	1546.9	28.9	10.3	311.3	313.2	64.0%	71.9%
	RW	1404.5	31.9	11.7	334.5	297.1	60.2%	68.1%
FIT	30%	811.4	46.7	18.2	466.4	220.2	41.8%	50.5%
	40%	972.7	40.8	15.3	424.9	254.2	49.1%	58.4%
	50%	1102.8	36.7	13.3	391.3	278.8	54.3%	63.8%
	60%	1229.3	33.2	11.8	361.9	295.8	58.5%	68.0%
	70%	1321.5	30.9	10.9	339.6	308.1	61.5%	70.5%
	100%	1585.5	25.6	8.7	286.9	333.1	68.0%	76.2%
	RW	1004.9	39.8	14.9	419.2	258.9	50.3%	59.6%
FOBT	30%	647.0	57.2	22.6	562.8	174.5	28.6%	38.7%
	40%	794.6	52.1	19.7	534.4	206.4	35.0%	46.5%
	50%	923.9	47.7	17.5	507.1	232.3	40.5%	52.3%
	60%	1040.4	44.1	15.6	485.1	256.6	44.9%	57.6%
	70%	1148.8	40.8	14.2	457.0	273.9	49.0%	61.3%
	100%	1426.6	33.8	11.2	392.8	306.6	57.8%	69.5%
	RW	698.3	55.3	21.6	551.5	185.1	30.9%	41.4%
Blood, S1	30%	820.6	60.0	24.3	576.1	151.3	25.1%	34.0%
	40%	938.5	57.0	22.5	563.0	172.9	28.9%	38.9%

nAAS=10% AAS=10%	50%	1030.0	54.6	21.2	548.5	188.1	31.9%	42.3%
	60%	1099.6	53.0	20.3	541.7	199.6	33.9%	44.9%
	70%	1157.2	51.7	19.6	535.7	208.0	35.5%	46.7%
	100%	1285.8	48.7	17.9	519.1	227.5	39.2%	51.3%
Blood, S2 nAAS=12.5% AAS= 15%	30%	920.4	54.0	21.9	523.3	175.0	32.6%	40.6%
	40%	1043.3	50.8	20.0	506.8	197.9	36.6%	45.6%
	50%	1146.0	48.1	18.6	487.9	214.4	40.0%	49.4%
	60%	1216.9	46.5	17.8	479.3	224.5	42.0%	51.7%
	70%	1275.4	44.8	16.8	468.1	235.8	44.1%	54.2%
	100%	1405.9	41.7	15.3	447.3	253.8	48.0%	58.4%
Blood, S3 nAAS=15% AAS= 15%	30%	967.2	52.3	21.1	509.2	183.4	34.7%	42.7%
	40%	1101.9	48.5	19.1	487.0	206.8	39.5%	48.0%
	50%	1194.8	46.1	17.9	471.0	221.6	42.5%	51.4%
	60%	1268.3	43.9	16.8	456.0	234.1	45.2%	54.5%
	70%	1339.8	42.3	16.0	445.9	242.9	47.2%	56.4%
	100%	1470.2	39.3	14.4	426.3	262.4	50.9%	60.8%
Blood, S4 nAAS=15% AAS= 20%	30%	1003.7	49.1	19.8	479.1	196.4	38.7%	46.1%
	40%	1134.9	45.6	17.9	460.1	219.7	43.1%	51.4%
	50%	1239.0	43.0	16.7	439.5	234.4	46.3%	54.6%
	60%	1316.4	40.9	15.5	424.0	247.7	49.0%	57.8%
	70%	1369.6	39.5	14.9	414.3	256.3	50.7%	59.4%
	100%	1505.7	36.4	13.4	391.7	272.9	54.5%	63.7%
Blood, S5 nAAS=20% AAS= 20%	30%	1089.2	45.5	18.2	451.3	212.5	43.2%	50.5%
	40%	1231.3	41.8	16.4	425.7	234.1	47.8%	55.5%
	50%	1334.8	39.1	15.0	407.3	250.4	51.2%	59.2%
	60%	1409.7	37.3	14.2	392.4	261.4	53.5%	61.5%
	70%	1472.6	35.7	13.4	380.2	270.2	55.4%	63.5%
	100%	1601.9	32.7	11.9	358.2	287.2	59.2%	67.6%

AAS, advanced adenoma (≥ 10 mm) sensitivity; COL, colonoscopy; CRC, colorectal cancer; FIT, fecal immunochemical test; FOBT, fecal occult blood test; LY, life-years; LYG, life-years gained; mt-sDNA, multi-target stool DNA; nAAS, non-advanced adenoma (<10 mm) sensitivity; RW, real-world; S, scenario.

Table S2. Estimated outcomes of sensitivity analyses with blood-based test under various adherence and expanded blood-based test adenoma sensitivity scenarios.

Blood-test sensitivity	Adherence	Total COLs	CRC cases	CRC deaths	LYG	CRC Incidence reduction	CRC Mortality reduction
nAAS=20% AAS= 30%	30%	1147.4	41.4	16.5	231.3	48.3%	55.1%
	40%	1279.0	37.7	14.7	252.6	53.0%	59.9%
	50%	1382.9	35.0	13.5	268.5	56.4%	63.3%
	60%	1462.4	33.0	12.6	278.8	58.8%	65.8%
	70%	1521.6	31.6	11.9	287.4	60.6%	67.7%
	100%	1647.9	29.0	10.9	300.7	63.8%	70.5%
nAAS=30% AA= 30%	30%	1288.7	36.1	14.4	253.1	54.9%	60.8%
	40%	1426.9	32.3	12.6	272.6	59.7%	65.7%
	50%	1526.3	29.9	11.5	287.9	62.7%	68.8%
	60%	1602.3	28.0	10.7	298.4	65.0%	71.0%
	70%	1665.2	26.9	10.1	305.6	66.4%	72.6%
	100%	1788.0	24.6	9.1	317.9	69.3%	75.2%
nAAS=25% AAS= 40%	30%	1263.3	35.3	14.2	256.7	55.9%	61.5%
	40%	1399.2	31.7	12.4	278.6	60.4%	66.3%
	50%	1499.4	29.2	11.2	293.3	63.5%	69.5%
	60%	1568.1	27.8	10.7	300.3	65.3%	71.0%
	70%	1629.4	26.7	10.1	307.5	66.7%	72.6%
	100%	1747.3	24.5	9.2	319.8	69.4%	75.1%
nAAS=40% AAS= 40%	30%	1430.8	29.5	11.8	281.9	63.2%	68.1%
	40%	1563.1	26.2	10.1	301.7	67.3%	72.4%
	50%	1662.6	23.9	9.2	313.7	70.1%	74.9%
	60%	1731.1	22.6	8.6	320.3	71.8%	76.5%
	70%	1790.6	21.8	8.2	325.9	72.8%	77.6%
	100%	1905.7	20.3	7.5	336.7	74.7%	79.5%

AAS, advanced adenoma (≥ 10 mm) sensitivity; COL, colonoscopy; CRC, colorectal cancer; LYG, life-years gained; nAAS, non-advanced adenoma (<10 mm) sensitivity.

Figure S1. Colorectal cancer incidence reduction (IR) per 1,000 patients screened over lifetime horizon based on different adherence rates blood-based test adenoma sensitivity at A) 10% and B) 20%. Numbers represent ranges of incremental IR versus the blood-based test. A positive value (green) indicates the stool-based test has less IR than the blood-based test, and a negative value (red/orange) indicates the stool-based test has more IR than the blood-based test. Adherence rates ranged from 100% or 30-70% for both stool- and blood-tests. FIT, fecal immunochemical test; FOBT, fecal occult blood test; mt-sDNA, multi-target stool DNA.

A)

	Screening adherence rate	mt-sDNA						Blood IR		Screening adherence rate	FIT						Blood IR		Screening adherence rate	FOBT						Blood IR
		30%	40%	50%	60%	70%	100%				30%	40%	50%	60%	70%	100%				30%	40%	50%	60%	70%	100%	
Blood Test	30%	-25%	-29%	-32%	-34%	-36%	-39%	25%	Blood Test	30%	-17%	-24%	-29%	-33%	-36%	-43%	25%	Blood Test	30%	-4%	-10%	-15%	-20%	-24%	-33%	25%
	40%	-21%	-25%	-28%	-30%	-32%	-35%	29%		40%	-13%	-20%	-25%	-30%	-33%	-39%	29%		40%	0%	-6%	-12%	-16%	-20%	-29%	29%
	50%	-18%	-22%	-25%	-27%	-29%	-32%	32%		50%	-10%	-17%	-22%	-27%	-30%	-36%	32%		50%	3%	-3%	-9%	-13%	-17%	-26%	32%
	60%	-16%	-20%	-23%	-25%	-27%	-30%	34%		60%	-8%	-15%	-20%	-25%	-28%	-34%	34%		60%	5%	-1%	-7%	-11%	-15%	-24%	34%
	70%	-14%	-19%	-22%	-24%	-25%	-29%	35%		70%	-6%	-14%	-19%	-23%	-26%	-33%	35%		70%	7%	0%	-5%	-9%	-14%	-22%	35%
	100%	-11%	-15%	-18%	-20%	-22%	-25%	39%		100%	-3%	-10%	-15%	-19%	-22%	-29%	39%		100%	11%	4%	-1%	-6%	-10%	-19%	39%
mt-sDNA IR		50%	54%	57%	59%	61%	64%		FIT IR		42%	49%	54%	59%	61%	68%		FOBT IR		29%	35%	41%	45%	49%	58%	

B)

	Screening adherence rate	mt-sDNA						Blood IR		Screening adherence rate	FIT						Blood IR		Screening adherence rate	FOBT						Blood IR
		30%	40%	50%	60%	70%	100%				30%	40%	50%	60%	70%	100%				30%	40%	50%	60%	70%	100%	
Blood Test	30%	-7%	-11%	-14%	-16%	-18%	-21%	43%	Blood Test	30%	1%	-6%	-11%	-15%	-18%	-25%	43%	Blood Test	30%	15%	8%	3%	-2%	-6%	-15%	43%
	40%	-2%	-6%	-9%	-11%	-13%	-16%	48%		40%	6%	-1%	-6%	-11%	-14%	-20%	48%		40%	19%	13%	7%	3%	-1%	-10%	48%
	50%	1%	-3%	-6%	-8%	-10%	-13%	51%		50%	9%	2%	-3%	-7%	-10%	-17%	51%		50%	23%	16%	11%	6%	2%	-7%	51%
	60%	4%	-1%	-4%	-6%	-7%	-10%	53%		60%	12%	4%	-1%	-5%	-8%	-15%	53%		60%	25%	18%	13%	9%	4%	-4%	53%
	70%	5%	1%	-2%	-4%	-5%	-9%	55%		70%	14%	6%	1%	-3%	-6%	-13%	55%		70%	27%	20%	15%	10%	6%	-2%	55%
	100%	9%	5%	2%	0%	-2%	-5%	59%		100%	17%	10%	5%	1%	-2%	-9%	59%		100%	31%	24%	19%	14%	10%	1%	59%
mt-sDNA IR		50%	54%	57%	59%	61%	64%		FIT IR		42%	49%	54%	59%	61%	68%		FOBT IR		29%	35%	41%	45%	49%	58%	

Figure S2. Colorectal cancer mortality reduction (MR) per 1,000 patients screened over lifetime horizon based on different adherence rates for blood-based test adenoma sensitivity at A) 10% and B) 20%. Numbers represent ranges of incremental MR versus the blood-based test. A positive value (green) indicates the stool-based test has less MR than the blood-based test, and a negative value (red/orange) indicates the stool-based test has more MR than the blood-based test. Adherence rates ranged from 100% or 30-70% for both stool- and blood-tests. FIT, fecal immunochemical test; FOBT, fecal occult blood test; mt-sDNA, multi-target stool DNA.

A)

		mt-sDNA						Blood MR
Screening adherence rate		30%	40%	50%	60%	70%	100%	
Blood Test	30%	-24%	-28%	-31%	-33%	-35%	-38%	34%
	40%	-19%	-23%	-26%	-29%	-30%	-33%	39%
	50%	-16%	-20%	-23%	-25%	-27%	-30%	42%
	60%	-13%	-17%	-20%	-22%	-24%	-27%	45%
	70%	-11%	-16%	-19%	-21%	-22%	-25%	47%
	100%	-7%	-11%	-14%	-16%	-18%	-21%	51%
mt-sDNA MR		58%	62%	65%	67%	69%	72%	

		FIT						Blood MR
Screening adherence rate		30%	40%	50%	60%	70%	100%	
Blood Test	30%	-17%	-24%	-30%	-34%	-36%	-42%	34%
	40%	-12%	-19%	-25%	-29%	-32%	-37%	39%
	50%	-8%	-16%	-22%	-26%	-28%	-34%	42%
	60%	-6%	-13%	-19%	-23%	-26%	-31%	45%
	70%	-4%	-12%	-17%	-21%	-24%	-30%	47%
	100%	1%	-7%	-13%	-17%	-19%	-25%	51%
FIT MR		50%	58%	64%	68%	70%	76%	

		FOBT						Blood MR
Screening adherence rate		30%	40%	50%	60%	70%	100%	
Blood Test	30%	-5%	-12%	-18%	-24%	-27%	-35%	34%
	40%	0%	-8%	-13%	-19%	-22%	-31%	39%
	50%	4%	-4%	-10%	-15%	-19%	-27%	42%
	60%	6%	-2%	-7%	-13%	-16%	-25%	45%
	70%	8%	0%	-6%	-11%	-15%	-23%	47%
	100%	13%	5%	-1%	-6%	-10%	-18%	51%
FOBT MR		39%	46%	52%	58%	61%	69%	

B)

		mt-sDNA						Blood MR
Screening adherence rate		30%	40%	50%	60%	70%	100%	
Blood Test	30%	-7%	-12%	-15%	-17%	-18%	-21%	50%
	40%	-2%	-7%	-10%	-12%	-13%	-16%	55%
	50%	1%	-3%	-6%	-8%	-10%	-13%	59%
	60%	4%	-1%	-4%	-6%	-7%	-10%	62%
	70%	6%	1%	-2%	-4%	-5%	-8%	63%
	100%	10%	5%	2%	0%	-1%	-4%	68%
mt-sDNA MR		58%	62%	65%	67%	69%	72%	

		FIT						Blood MR
Screening adherence rate		30%	40%	50%	60%	70%	100%	
Blood Test	30%	0%	-8%	-13%	-17%	-20%	-26%	50%
	40%	5%	-3%	-8%	-12%	-15%	-21%	55%
	50%	9%	1%	-5%	-9%	-11%	-17%	59%
	60%	11%	3%	-2%	-6%	-9%	-15%	62%
	70%	13%	5%	0%	-4%	-7%	-13%	63%
	100%	17%	9%	4%	0%	-3%	-9%	68%
FIT MR		50%	58%	64%	68%	70%	76%	

		FOBT						Blood MR
Screening adherence rate		30%	40%	50%	60%	70%	100%	
Blood Test	30%	12%	4%	-2%	-7%	-11%	-19%	50%
	40%	17%	9%	3%	-2%	-6%	-14%	55%
	50%	20%	13%	7%	2%	-2%	-10%	59%
	60%	23%	15%	9%	4%	0%	-8%	62%
	70%	25%	17%	11%	6%	2%	-6%	63%
	100%	29%	21%	15%	10%	6%	-2%	68%
FOBT MR		39%	46%	52%	58%	61%	69%	